<DOC>
	<DOCNO>NCT00843440</DOCNO>
	<brief_summary>The efficacy anti-VEGF treatment Bevacizumab case HHT consider molecular mechanism imply angiogenesis HHT , well mechanisms action type treatment . Two article recently report spectacular improvement thanks Bevacizumab patient HHT complicate severe liver involvement cardiac effect support u sense . Up , treatment recommend severe hepatic form HHT liver transplant , disadvantage multiple well know : long waiting list , surgical morbidity mortality , immunosuppressive treatment life . Furthermore , treatment Bevacizumab contraindication , drug ineffective , subsequent liver transplant necessary .</brief_summary>
	<brief_title>Efficacy Safety Bevacizumab Treatment Hemorrhagic Hereditary Telangiectasia ( HHT ) Associated With Severe Hepatic Vascular Malformations . Phase II Study</brief_title>
	<detailed_description />
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Telangiectasis</mesh_term>
	<mesh_term>Vascular Malformations</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>General criterion : Age ≥ 18 year &lt; 70 year Subjects must give free enlighten consent sign consent form . HHT related criterion Patients monitor clinically confirm HHT disease . Patients severe liver involvement relationship HHT disease Patients high cardiac output ultrasound . Associated disease relate criterion Blood : neutrophil ≥ 1.0x109 / L platelets ≥ 100x109 / L. INR ( International Normalized Ratio ) ≤ 1.5 ( except patient anticoagulant ) TCA ≤ 1.5 x upper limit standard laboratory Renal function : creatinine ≤ 1.25 x upper limit standard laboratory . Patients proteinuria strip ≥ 2 + control Proteinuria 24 hour ≤ 1g / 24 hour • General criterion Women pregnant liable become pregnant course trial . Patients reach majority protect term law ( French public health code ) . Refusal give enlighten consent . Patients affiliate health insurance regime • Criteria medical history Patients diagnosis HHT disease confirm . The presence atrial fibrillation electrocardiogram inclusion . The presence cerebral arteriovenous malformation angioMRI do year prior inclusion . Existence diverticulitis colon sigmoid Thrombosis within 6 month inclusion Infectious disease treat antibiotic unresolved inclusion . Patients blood pressure control time inclusion ( systolic blood pressure &gt; 150 mmHg / diastolic &gt; 100 mmHg ) without treatment . Patients high blood pressure include blood pressure number standardize appropriate medical treatment . • Surgical criterion Major surgery ( include open biopsy ) severe trauma within 28 day precede start treatment . • Medical treatment Current recent use non steroidal antiinflammatory drug antiplatelet therapy 10 day first administration Bevacizumab . Use oral parenteral anticoagulant thrombolytic agent within 28 day precede inclusion ( anticoagulant give prophylactically permit ) . Participation another clinical trial within 28 day precede inclusion . Vaccination live vaccine yellow fever treatment period . Administration phenytoin ( Dihydan ® DILANTIN ® ) treatment period . • Allergy Hypersensitivity active substance excipients . Hypersensitivity product make Chinese hamster ovary ( CHO ) cell human humanize recombinant antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>Antiangiogenic therapy</keyword>
	<keyword>Bevacuzimab</keyword>
	<keyword>Hemorrhagic Hereditary Telangiectasia ( HHT ) severe liver involvement</keyword>
</DOC>